Vistagen Therapeutics (NASDAQ:VTGN) released its earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01, Fidelity Earnings reports.
Shares of NASDAQ VTGN traded up $0.07 on Friday, reaching $1.08. 296,700 shares of the company traded hands, compared to its average volume of 316,562. Vistagen Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.06. The company has a 50 day moving average of $1.16 and a 200 day moving average of $0.83. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 2.44. The stock has a market capitalization of $46.20 million, a PE ratio of -1.20 and a beta of -0.29.
A number of research analysts have issued reports on the stock. Maxim Group set a $4.00 target price on shares of Vistagen Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 15th. William Blair restated a “buy” rating on shares of Vistagen Therapeutics in a report on Wednesday, October 9th. Chardan Capital restated a “hold” rating and issued a $0.70 target price on shares of Vistagen Therapeutics in a report on Sunday, November 3rd. Finally, ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $2.35.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Article: What does a neutral rating on stocks mean?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.